- Home
- OPRX vs LPTX Comparison
OPRX vs LPTX Comparison
Compare OPRX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- LPTX
- Stock Information
- Founded
- OPRX 2006
- LPTX 2011
- Country
- OPRX United States
- LPTX United States
- Employees
- OPRX N/A
- LPTX N/A
- Industry
- OPRX Business Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPRX Consumer Discretionary
- LPTX Health Care
- Exchange
- OPRX Nasdaq
- LPTX Nasdaq
- Market Cap
- OPRX 111.2M
- LPTX 108.4M
- IPO Year
- OPRX N/A
- LPTX N/A
- Fundamental
- Price
- OPRX $4.91
- LPTX $2.91
- Analyst Decision
- OPRX Buy
- LPTX Strong Buy
- Analyst Count
- OPRX 6
- LPTX 3
- Target Price
- OPRX $8.25
- LPTX $7.50
- AVG Volume (30 Days)
- OPRX 335.3K
- LPTX 455.1K
- Earning Date
- OPRX 11-13-2024
- LPTX 11-13-2024
- Dividend Yield
- OPRX N/A
- LPTX N/A
- EPS Growth
- OPRX N/A
- LPTX N/A
- EPS
- OPRX N/A
- LPTX N/A
- Revenue
- OPRX $88,179,506.00
- LPTX N/A
- Revenue This Year
- OPRX $27.42
- LPTX N/A
- Revenue Next Year
- OPRX $11.97
- LPTX N/A
- P/E Ratio
- OPRX N/A
- LPTX N/A
- Revenue Growth
- OPRX 40.40
- LPTX N/A
- 52 Week Low
- OPRX $3.78
- LPTX $1.68
- 52 Week High
- OPRX $16.65
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- OPRX 45.73
- LPTX 47.52
- Support Level
- OPRX $4.62
- LPTX $2.75
- Resistance Level
- OPRX $5.61
- LPTX $3.12
- Average True Range (ATR)
- OPRX 0.45
- LPTX 0.31
- MACD
- OPRX -0.00
- LPTX -0.02
- Stochastic Oscillator
- OPRX 23.58
- LPTX 23.41
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .